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Background/aims: To investigate the alterations of brain-derived neurotrophic factor (BNDF)
serum levels in subjects with different intensity of cognitive impairment and different
neurodegenerative processes.
Material and methods: Serum BDNF levels were analyzed by ELISA kit in 378 subjects: 134
Alzheimer's disease (AD) patients, 115 amnestic mild cognitive impairment (MCI) patients,
and 129 controls divided into two groups: neurodegenerative control group (ND), consisting
of 49 Parkinson's disease patients without any cognitive complaints, and cognitively normal
control group (CN), consisting of 80 subjects without any neurological disorders.
Results: AD patients had signiﬁcantly lower ( p < 0.001) BDNF serum levels compared to MCI,
CN and ND controls. Age and education had signiﬁcant inﬂuence on BDNF serum levels
regardless the diagnosis or group assignment. We have found no inﬂuence of depression on
BDNF serum levels either in our group as a whole, or in each group assessed separately. We
found signiﬁcant correlation between BDNF serum levels and cognitive impairments. After
multiple comparisons between the groups, we found that, after adjustment for confounding
factors (age, gender, education, depression, cognitive impairment), BDNF serum levels were
the lowest in AD group ( p = 0.05).
Conclusions: Advanced age and low educational level are associated with decreased BDNF
serum levels. Decreased BDNF serum levels correspond to the severity of cognitive im-
pairment. There is no correlation between BDNF serum levels and depressive symptoms.
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The most common form of neurodegenerative disorders is
Alzheimer's disease (AD) affecting over 20 million people all
over the world [1,2]. Dementia in AD is related to progressive
neurodegeneration, which is characterized by synaptic injury
and neuronal loss associated with the formation of senile
plaques composed of amyloid-b (Ab) oligomers and intracel-
lular neuroﬁbrillary tangles (NFT) composed of hyperpho-
sphorylated tau protein [3–5]. The earliest pathological
changes usually occur in medial temporal lobe structures,
interrupting the neural network critical for episodic memory
function (e.g., free recall, recognition, paired-associate learn-
ing). Mildly demented AD patients are also impaired on tests of
object naming and semantic categorization, that reﬂect
deterioration in the structure and content of semantic
memory (i.e., general knowledge of facts, the meanings of
words) that supports language. Knowledge for particular items
or concepts and the associations between them may be
disrupted as the neuropathology of AD spreads throughout the
temporal, frontal, and parietal association cortices in which
they are thought to be diffusely stored. Deﬁcits in executive
functions, responsible for the mental manipulation of infor-
mation, concept formation, and problem solving can occur
early in the course of AD, and in addition to difﬁculties with
delayed memory recall may predict disease progression.
Deﬁcits in executive functioning have been hypothesized to
reﬂect AD pathology, especially neuroﬁbrillary tangle burden
in prefrontal cortex [2–4,6]. Recently, there has been increasing
evidence that alterations in the brain neurotrophic support
and in particular in the brain-derived neurotrophic factor
(BDNF) expression and signaling might contribute to neuro-
degeneration [7,8]. The BDNF is a member of the neurotrophin
family of proteins that is not only important for the normal
development of the peripheral and central nervous system,
but also plays a key role in neuronal survival, synaptic
plasticity, axonal guidance, cell morphology, memory forma-
tion and cognition in the adult brain [8–11]. The BDNF is highly
concentrated in the nervous system. The BDNF produced in
brain neurons acts locally at synapses, and is not released and
transported from the brain to periphery [12]. Circulating BDNF
in platelets is produced from megacaryocytes and stored in a-
granules, which do not receive their content from external
sources [13]. It is speculated that, the variance of circulating
BDNF may partly reﬂect the variance of BDNF secretion in the
human brain, and reduced brain BDNF levels could be
associated with lower circulating BDNF levels [14]. The
reduction of BDNF concentration in hippocampus and cerebral
cortex may induce a neurodegenerative process in the human
brain [15].
BDNF serum concentration was reported to be signiﬁcantly
reduced in patients with severe dementia comparing to
control subjects [15,16]. Additionally, higher BDNF serum
levels were associated with better neuropsychological func-
tioning in healthy elderly subjects [17,18]. The correlation
between the BDNF serum levels and dementia has been
analyzed in AD patients with mixed results. While some
researchers found a decrease in BDNF serum concentrations in
AD [15], others reported increased BDNF levels in patients inthe early as well as in advanced stages of AD [19,20]. The BDNF
levels were found to be signiﬁcantly negatively associated with
the scores on immediate and delayed verbal memory and
immediate visual memory [21]. Other studies showed that
BDNF serum levels correlate positively with performance on
neuropsychological tests investigating executive functioning
and attention [22]. Moreover, BDNF was recognized as a potent
inhibitor of apoptosis-mediated cell death and neurotoxin-
induced degeneration of dopaminergic neurons. The decrease
of BDNF was detected in the substantia nigra in PD [23]. Lower
BDNF serum levels were reported in early stages of Parkinson's
disease, and the increase of BDNF levels was reported with the
disease progression suggesting a compensatory mechanism
involved in more advanced stages of Parkinson's disease
[24,25].
The current study aims to contribute to the discussion on
the involvement of BDNF in neurodegenerative diseases by
assessing alterations of peripheral BDNF levels. It replicates
and extends previous ﬁndings by comparing BDNF serum
levels in a group of patients with the Alzheimer's dementia
and with patients diagnosed with the mild cognitive im-
pairment (MCI), which is a clinical concept proposed by the
Mayo Clinic Group in 1999 [26]. MCI is placed between normal
aging and dementia with 5–8% annual progression rate to AD
[27]. Patients were compared with two types of controls: a
subgroup of cognitively normal subjects without any known
neurological disorders and a subgroup of subjects with the
idiopathic Parkinson's disease with a normal cognitive status.
We decided to include PD patients as an additional control
group to examine if BDNF serum levels would depend on a type
of a neurodegenerative process.
2. Materials and methods
2.1. Study population
The subjects in the study were: 134 Alzheimer's disease
patients (81 females and 53 males with the mean age of 72.2
 9.4 years), 115 amnestic MCI patients (67 females and 48
males with the mean age of 71.1  9.6 years), and 129 controls
subdivided into two groups: a neurodegenerative control
group (ND), consisting of 49 Parkinson's disease patients
without any cognitive deﬁcits (22 females and 27 males with
the mean age of 63.3  10.5 years), and a cognitively-normal
control group (CN), consisting of 80 subjects without any
neurological disorders (44 females and 36 males with the mean
age of 65.6  11.9 years) (Table 1). Patients and ND controls
were recruited from the outpatient clinic at the Department of
Neurology. The subjects in the CN control group were
independently functioning community dwellers without any
subjective complaints on cognitive impairment and without
any movement disorder symptoms. All patients and control
subjects were right-handed. A written informed consent to
participate in the study was obtained from each participant.
The study was approved of by the Local Ethics Committee for
Medical Research.
All the patients were examined by neurologists with
expertise in neurodegenerative diseases (dementia and
movement disorders) and met the internationally accepted
Table 1 – Demographic, clinical and BDNF serum levels of different studied groups.
Diagnosis Controls CN Controls ND MCI AD p-Value
Sample size N (100%) 80 (21.2%) 49 (13.0%) 115 (30.4%) 134 (35.4%) <0.001
Demographic variables
Age (years  SD) 65.6  11.9 63.3  10.5 71.1  9.6 72.2  9.4 0.8
Gender F/M (M%) 44/36 (45.0%) 22/27 (55.1%) 67/48 (41.7%) 81/53 (39.5%) 0.1
Education (years  SD) 13.5  2.5 12.5  2.7 12.2  3.6 10.7  2.7 0.9
Disease duration (years  SD) NA 8.41  5.8 1.77  1.3 3.02  2.0 NA
Clinical variables
MMSE (pts  SD) 28.8  1.4 27.2  2.4 26.5  2.4 16.1  6.4 <0.001
BDI (pts  SD) 14.17  7.2 10.8  9.9 11.7  7.5 7.84  6.7 <0.05
CDT (pts  SD) 9.64  1.1 8.69  2.4 7.9  2.7 3.4  3.7 <0.001
Hoehn-Yahr (stage  SD) NA 2.7  0.7 NA NA NA
Treatment
AChEI (+/) NA (0/49) (0/115) (134/0) NA
L-dopa (+/) NA (49/0) NA (0/134) NA
LEDD (mg  SD) NA 940.2  493.8 NA NA NA
BDNF
ng/ml  SD 10.0  4.0 9.2  4.7 8.7  6.1 4.8  4.7 <0.001
Median (IQR) 9.3 (5.3) 8.0 (7.3) 7.1 (12.2) 2.4 (4.3)
Controls CN, cognitively normal controls; Controls ND, neurodegenerative controls with Parkinson's disease without cognitive impairment;
MCI, mild cognitive impairment; AD, Alzheimer's disease; MMSE, Mini Mental State Examination; BDI, Beck Depression Inventory; CDT, Clock
Drawing Test, BDNF, brain-derived neurotrophic factor; IQR, Interquartile range; NA, not applicable; AChEI, acetylocholin esterase inhibitors;
LEDD, L-dopa equivalent daily dose; (+/), treated/not treated.
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disease [2,3] or Parkinson's disease [28,29].
All the subjects underwent clinical evaluation that included
previous medical history, followed by physical, neurological
and neuropsychological examination. Prior to the study, each
individual underwent laboratory tests and structural imaging
scanning of the brain for the exclusion of secondary causes of
cognitive deﬁcit and movement disorders.
All subjects with medical, psychiatric or neurological
disorders (other than MCI, AD, PD) that could interfere with
cognitive performance or could cause parkinsonism, were
excluded from the study.
2.2. Cognitive assessment
All the patients and controls were examined in the morning
hours. The Parkinson's disease patients were evaluated in ON
state, to avoid the inﬂuence of movement disorder symptoms
on tests results. The general cognitive status was assessed
with the Mini-Mental State Examination (MMSE) [30] and the
Clock Drawing Test (CDT) scored by the Sunderland method
[31,32]. A battery of detailed cognitive tests, performed by a
clinical psychologist, was used to assess the cognitive status of
every subject [33,34]. Episodic memory was assessed with the
Rey Auditory Verbal Learning Test (AVLT). The language
abilities were assessed with categorial and phonetic verbal
ﬂuency tests. Executive functions and attention were evaluat-
ed with the Trail Making Test (TMT parts A and B). The Beck
Depression Inventory (BDI) was used to evaluate depressive
symptoms [35]. The ﬁnal diagnosis of cognitive status was
made individually as a consensus of a neurologist's and
neuropsychologist's opinion. Additionally the data obtained
from the patient's informant (caregiver) were taken into
consideration. The subjects were classiﬁed as cognitivelynormal if they had no subjective complaints and there was no
objective memory impairment in the clinical assessment. The
diagnosis of MCI was made according to the Mayo Clinic Group
criteria [27]. The dementia diagnosis was made according to
DSM IV and the Alzheimer's disease was diagnosed according
to the NINCDS-ADRDA criteria [2,3].
2.3. Measurements
Blood samples were collected after overnight fasting. Venous
blood (5 ml) from the upper arm of each subject was collected
into anticoagulant free tubes. The samples were incubated at a
temperature of 4 degree Celsius (8C) for half an hour before the
serum was isolated. The samples were then centrifuged at
2000  g for 10 min. The supernatants were transferred to an
Eppendorff tube and stored at 70 8C before testing. The
concentration of BDNF in the serum was measured by a
standard protocol using the RayBio® Human BDNF Enzyme-
Linked Immunosorbent Assay (ELISA) kit [36].
2.4. Statistical analysis
Statistical analyses were performed using the R 3.1.2 software
on GNU GPL license and the STATISTICA 10.0 Stat Soft Polska
software. The measurable data analyses were done using
mean values and standard deviations (SD) in the case of
normal distribution, and the median with interquartile range
(IQR) for skewed distribution. Testing for normality of
distribution was performed with the Shapiro–Wilk test.
The t-test or the U Mann–Whitney test, depending on the
distribution of normality, were used to assess the signiﬁcance
of differences in values of BDNF in two groups (taking into
account a dichotomous variable: gender – female/male). The
Kruskal–Wallis test by ranks was used to compare three or
Fig. 1 – BDNF serum levels in all studied groups. Controls
CN, cognitively normal control group; Controls ND,
neurodegenerative control group (Parkinson's disease
patients without cognitive impairment); MCI, mild
cognitive impairment; AD, Alzheimer's disease; rectangle,
mean value of BDNF W SD; vertical line, range of BDNF
(from lowest to highest value).
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into account ordinal variables: age (years); education (years);
cognitive impairment – no dementia/mild dementia/moderate
dementia/severe dementia; depressive disorders – no depres-
sion/mild symptoms/moderate symptoms/severe symptoms).
Spearman's rank correlation coefﬁcients with 95% conﬁdence
intervals (95% CI) were used to measure statistical dependence
between variables. A two-way Permutational Multivariate
Analysis of Variance (ANOVA) was used to analyze the
inﬂuence of confounding factors, e.g., age, gender or education
on the differences in BDNF serum levels between groups.
Statistical signiﬁcance was assessed by permutational pair-
wise comparisons between group levels. The signiﬁcance level
was established at p < 0.05.
3. Results
Demographic information for controls and patients is reported
in Table 1. Differences in BDNF serum levels in controls and
patients with different neurodegenerative disorders are pre-
sented in Fig. 1. AD patients had signiﬁcantly lower (p < 0.001)
BDNF serum levels compared to MCI, CN and ND controls. MCI
patients had signiﬁcantly lower (p < 0.05) BDNF serum levels
compared to CN controls, but not to ND controls (p > 0.05). CN
and ND controls did not different signiﬁcantly in BDNF serum
levels (p > 0.05). The signiﬁcant effects of age, education and
cognitive impairment variables on BDNF serum levels were
observed in our sample. There was a signiﬁcant association
between BDNF serum levels and the number of years of
schooling (p < 0.01) (Table 2).Table 2 – BDNF serum levels in cases and controls with regard
depressive symptoms – total.
N (%) BDNF
Gender
Female 214 (56.7%) 
Male 164 (43.3%) 
Age (years)
≤65 97 (25.7%) 
65+ 281 (74.3%) 
Education (years)
General (≤8) 59 (15.6%) 
Vocational (9–10) 80 (21.1%) 
High school (11–12) 136 (35.9%) 
Higher education (≥13) 103 (27.4%) 
Cognitive impairment
No dementia 242 (64.1%) 
Mild symptoms 49 (12.9%) 
Moderate symptoms 63 (16.6%) 
Severe symptoms 24 (6.4%) 
Depressive disorders
No depression 229 (60.6%) 
Depressive symptoms 149 (39.4%) 
Mild symptoms 128 (33.8%) 
Moderate symptoms 14 (3.7%) 
Severe symptoms 7 (1.9%) 
BDNF, brain-derived neurotrophic factor; IQR, interquartile range.Next, we analyzed each group separately (Online Resource –
Suppl. Figure 1, Suppl. Tables 1 and 2). The two-way analysis of
variance (ANOVA) conﬁrmed that age and education had
signiﬁcant inﬂuence on BDNF serum levels regardless of the
diagnosis or group assignment. Interestingly, in the MCI group
the BDNF serum levels were higher in older population, but
this difference did not reach signiﬁcance (p > 0.05). to gender, age, education, cognitive impairment, and
 ng/ml  SD Median (IQR) p-Value
7.4  5.4 6.0 (8.7) 0.4
8.0  5.6 6.7 (10.3)
8.5  5.6 7.4 (10.2) <0.05
7.2  5.4 6.1 (8.8)
5.7  5.2 2.9 (6.2) <0.01
8.6  6.1 7.2 (11.2)
8.0  5.6 7.0 (10.2)
8.6  4.8 8.6 (7.6)
9.1  5.3 8.3 (9.3) <0.001
5.4  5.4 2.4 (6.5)
5.3  4.6 3.1 (5.8)
3.7  3.9 2.1 (3.3)
6.6  5.1 5.3 (8.8) 0.5
7.4  5.8 5.7 (10.2)
7.3  5.7 5.7 (10.2)
6.4  5.4 3.9 (9.2)
9.9  7.1 9.9 (13.8)
Fig. 2 – Spearman's correlation coefficient between BDNF serum levels and neuropsychological tests results – total. MMSE,
Mini Mental State Examination; AVLT, auditory verbal learning test; TMT A&B, trail making test parts A&B.
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MCI and cognitively normal control group, but we found
signiﬁcantly lower BDNF serum levels in males compared to
females in the neurodegenerative control group of subjects
with Parkinson's disease.
The depressive symptoms were present in the one-third of
the studied group (Table 2). We have found no inﬂuence of the
severity of depressive symptoms on variability in BDNF serum
levels either in the whole tested population or in each group
separately (Online Resource – Suppl. Table 2). After multiple
comparisons between the groups, we found that, afﬁliation to
the Alzheimer's disease group was the strongest factor
inﬂuencing the BDNF serum levels.
A signiﬁcant correlation between BDNF serum levels and
cognitive impairments, as measured by scores on the MMSE,
was observed in the tested sample (Table 2, Fig. 2). Analogous-
ly, the following signiﬁcant correlations were found between
BDNF serum levels and different domains of cognitive
impairment measured by the neuropsychological tests. A
positive correlation was found between BDNF serum levels
and episodic memory, as measured by the number of words
memorized and recalled after the delay in AVLT, and the
number of words in verbal ﬂuency tests. A negative correlation
was found between BDNF serum levels and the time tocomplete tasks in TMT A&B used to assess executive function
impairment (R0 = 0.41 and R0 = 0.31 respectively, p < 0.001).
None of the tests turned out to be speciﬁc, but all tests showed
signiﬁcant correlation coefﬁcients with BDNF serum levels
(Online Resource – Suppl. Table 3).
4. Discussion
The main goal of our study was to evaluate alteration of BNDF
serum levels in subjects with different intensity of cognitive
impairment caused by neurodegenerative processes.
Signiﬁcantly lower BDNF serum levels were detected in our
sample of patients with AD, which is in accordance with the
previous results [7,37]. The decreased level of peripheral BDNF
concentration was previously reported in patients with AD,
depending on the severity of the disease [15,38,39]. Most of our
AD patients were already in more severe stages of the disease,
with the mean MMSE score of 16.6 pts., reﬂecting the moderate
dementia syndrome. The AD patients had the lowest BDNF
serum levels out of all the examined subjects with neurode-
generative disorders. However, it should be pointed out that
neither dementia nor mild cognitive impairment was present
in our neurodegenerative control group of PD patients. Other
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well. Signiﬁcantly increased BDNF serum levels were found in
the early stages compared to low BDNF serum levels in the
severe stages of AD, which may be explained by a compensa-
tory increase in BDNF in early dementia [19]. To conﬁrm the
hypothesis that there is a link between the severity of
cognitive deﬁcit and BNDF serum levels, we assessed MCI
patients separately and found decreased BDNF serum levels in
this group. Nonetheless, BDNF serum levels were signiﬁcantly
lower in the AD group than in the MCI group conﬁrming a
correlation between BDNF serum levels and cognitive im-
pairment severity. Decreased serum BDNF levels in the
preclinical stage of AD suggest that BDNF deﬁciency with lack
of trophic support may play a pivotal role in a neurodegenera-
tive process [39]. Inconsistent results regarding BDNF serum
levels in dementia syndrome reported in the literature may, at
least partially, be explained by differences in the criteria of
patient recruitment, inclusion and exclusion used in the
previous studies, and differences in methodology used to
classify MCI group. Similarly, low BDNF serum levels in our
MCI group may be explained by the fact that this group was not
representative of the whole population. The patients were
recruited in a neurodegenerative disorders clinic located in a
tertiary care hospital, where strict criteria are used to
recognize MCI subjects with high probability of future
dementia development.
The three demographic variables: gender, age and educa-
tion level, were previously found to be possible confounding
factors determining the BDNF serum levels [39]. Some data
suggest that women have higher BDNF serum levels than men
[39], but other reports give contrasting results [40]. The
differences in BDNF serum levels in men and women might
be related to sex hormone differences. Most female subjects in
our population were postmenopausal, resulting in the insig-
niﬁcant effect of gender on BDNF serum levels in our sample.
Despite the diagnosis, a signiﬁcant effect of age and education
on BDNF serum levels was observed in our sample. Elderly
patients had lower BDNF serum levels than younger patients,
which is in concordance with the results from previous studies
[39,18,41]. Interestingly, in the MCI group the BDNF serum
levels were higher in older population, but this difference did
not reach signiﬁcance.
Most of our subjects had ﬁnished high school, and there
were no signiﬁcant differences in the educational level
between the investigated groups, however a low level of
education indicated lower BDNF serum levels. Opposite results
were found in the MCI group, where highly educated patients
had lower BDNF serum levels. MCI usually has multifactorial
etiology, where cardiovascular pathology coexists with a
neurodegenerative process [27]. Well-educated adults are
more likely to seek medical help, therefore, appropriate
prevention and treatment of modiﬁable risk factors of
dementia is more often and earlier conducted in this group.
Consequently, in this group, mild cognitive impairment is
more often caused by the neurodegenerative process and
Alzheimer's disease is more likely to develop [42].
The results of the battery of neuropsychological tests
correlated with the BDNF serum levels. The observed
relationship between lower BDNF serum levels and impaired
episodic memory, and between executive functions andprocessing speed is consistent with previous studies [38,39].
We found no differences favoring a single cognitive domain by
comparing BDNF serum levels and different tests assessing
episodic memory, verbal ﬂuency and executive functions.
Depressive disorders are common in subjects with cogni-
tive impairment. Depression may precede, accompany or
follow dementia [43]. Some studies indicated that peripheral
BDNF can be used as a biomarker of mood state and disease
progression for mood disorders, including major depressive
disorder [40,44,45]. In our studied group there were no patients
with severe depression as diagnosed by a consulting psychia-
trist. We found no correlation between BDNF serum levels and
depressive symptoms in our sample. Our results are in line
with the studies of Bus et al., who found that, the severity of
depressive symptoms is not signiﬁcantly associated with
BDNF serum levels, and with Curto et al., who assessed BDNF
serum levels in Alzheimer's disease patients with and without
depression, and found no signiﬁcant correlation between
Geriatric Depression Scale score and BDNF serum levels
[46,47]. We are aware that the presence of some depressive
symptoms found in self-reported inventory such as Beck
Depression Inventory cannot be recognized as synonymous
with depression diagnosis. This may explain why our results
stand in contrast to the previous reports regarding full blown
depressive disorder [44,45,48].
Some limitations of our investigation should be discussed.
No data on cardiovascular risk factors of dementia were
gathered in our study to be available for statistical evaluation.
However, in a recent studies, the importance of BDNF was
suggested in high cardiovascular risk conditions, such as
obesity, metabolic syndrome, and coronary atherosclerosis
[49,50]. In a study by Ejiri et al., patients with unstable angina
have been reported to have increased BDNF levels in the
coronary circulation compared with individuals with stable
angina, suggesting that BDNF may detrimentally inﬂuence
atherosclerotic plaque stability [51]. Conversely, Manni et al.
reported lower BDNF plasma levels in the acute coronary
syndrome cases compared with the controls, suggesting a
protective role of BDNF [49]. Studies by Krabbe and Kaess have
also shown, that higher BDNF levels is associated with lower
risk of cardiovascular disease events and death, indepen-
dently of standard risk factors [52,53]. In a study of Nemcsik
et al., BDNF serum levels were elevated in a chronic
hypertensive patients, and authors suggested that BDNF
could play a role in a compensatory mechanism targeting
peripheral neurons and vascular cells [54]. Moreover, de-
creased BDNF serum level was found to be associated with
increased risk of incident stroke [55]. Circulating BDNF was
reported to be increased in obese women, and high BDNF
levels were observed in subjects with metabolic syndrome
[56], while other studies shown low BDNF concentrations in
subjects with obesity [52]. On the other hand, serum BDNF was
not associated with fat components of the body in a study of
Lee et al., and no correlation between BDNF serum levels and
obesity was found by Gajewska et al. [57,58]. Alterations in
BDNF serum levels in patients with type 2 diabetes (T2DM)
have also been studied, but the conclusions are inconsistent.
Some researchers reported decreased circulating BDNF levels
in T2DM patients [50], while other studies shown increased
serum BDNF levels in these patients [59].
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level is probably dependent on a neurodegenerative process as
in Alzheimer's disease. At present, since there is no cure for
neurodegenerative diseases, physical activity, rehabilitation
and motor function training that improve health status of
patients and elderly adults should be recommended, because
research ﬁndings suggest it positively inﬂuences the BNDF
levels [60]. Modulating BDNF signaling may be a future
promising therapeutic concept for reducing the risk of
neurodegenerative diseases and future investigations are
warranted.
5. Conclusions/highlights
Advanced age and low educational level are associated with
decreased BDNF serum levels. Decreased BDNF serum levels
correspond to the severity of cognitive impairment. No
correlation was found between BDNF serum levels and
depressive symptoms.
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